NEW YORK (GenomeWeb News) – British science services firm LGC today said that it has licensed Abbott's Ibis T5000 Biosensor System and will work with Abbott to develop commercial applications for the molecular diagnostics platform.
Under terms of the alliance, the partners will jointly identify and develop commercial diagnostic applications for the T5000, which is currently sold for research uses. LGC received an exclusive license to develop non-clinical applications in the UK and a non-exclusive license to develop clinical and food-testing applications.
LGC also said that it intends to launch a microbial identification diagnostics service built around the T5000. The firm noted that "a number of US agencies involved in pathogen and infection control" are using the system.
Further terms of the licensing and development deal were not disclosed.
The T5000 system employs a combination of PCR and mass spectrometry for rapidly identifying and characterizing microorganisms. The system was developed by Ibis Biosciences, which Abbott purchased from Isis Pharmaceuticals in January for total consideration of $215 million plus earn-out payments.
Abbott has previously said that it intends to seek US Food and Drug Administration clearance of the system for clinical diagnostics applications.